Teva price target lowered to $27 at UBS, says pullback ‘somewhat unfair’

UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock Wednesday was “somewhat unfair” given 2025 is a “unique” year in terms of margin evolution, and that the firm sees a path to operating margin expansion in 2026-2026, but is lowering its expectations as the starting point is now lower. The firm says the valuation is attractive, and sees potential beat and raises during 2025, which can drive stock recovery from here, the analyst tells investors in a research note.